[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis

B Tomasik, M Bieńkowski, M Braun, S Popat… - Lung Cancer, 2021 - Elsevier
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …

Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer

L Zhou, X Wei - Frontiers in Immunology, 2021 - frontiersin.org
Immune checkpoint inhibitors (ICIs) are novel immunotherapy-based drugs that have
become increasingly popular in the treatment of lung cancer. Researchers have recognized …

Impact of patient age on clinical efficacy and toxicity of checkpoint inhibitor therapy

SK Wong, CA Nebhan, DB Johnson - Frontiers in Immunology, 2021 - frontiersin.org
The addition of immune checkpoint inhibitors (ICIs) to the therapeutic armamentarium for
solid malignancies has resulted in unprecedented improvements in patient outcomes in …

Aging, cancer, and antitumor immunity

H Ikeda, Y Togashi - International Journal of Clinical Oncology, 2022 - Springer
Aging leads to numerous changes that affect many components of the immune system,
called “immunosenescence”. Indeed, elderly individuals exhibit dysregulated immune …

[HTML][HTML] Impact of aging on immune-related adverse events generated by anti–programmed death (ligand) PD-(L) 1 therapies

C Baldini, PM Romano, AL Voisin, FX Danlos… - European Journal of …, 2020 - Elsevier
Background Aging is an important risk factor for cancers and is associated with poor
prognosis. Weakness of the immune system, also called immunosenescence may occur with …

The effects of age and systemic metabolism on anti-tumor T cell responses

JM Drijvers, AH Sharpe, MC Haigis - Elife, 2020 - elifesciences.org
Average age and obesity prevalence are increasing globally. Both aging and obesity are
characterized by profound systemic metabolic and immunologic changes and are cancer …

Immune checkpoint inhibitor‐related adverse events in lung cancer: Real‐world incidence and management practices of 1905 patients in China

Y Shi, J Fang, C Zhou, A Liu, Y Wang, Q Meng… - Thoracic …, 2022 - Wiley Online Library
Abstract Background Immune checkpoint inhibitors (ICIs) are the standard treatment for
advanced lung cancer, but immune‐related adverse events (irAEs) remain poorly …

The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer

S Zhang, X Bai, F Shan - International Immunopharmacology, 2020 - Elsevier
Recently, immunotherapy has evolved into a true treatment modality with the approval of PD-
1 and PD-L1 inhibitors as the standard care for first-line treatment in patients with non-small …

[HTML][HTML] Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer

G Pasello, A Pavan, I Attili, A Bortolami… - Cancer treatment …, 2020 - Elsevier
Immune checkpoint inhibitors (ICIs) targeting programmed death 1 (PD-1) and PD-ligand 1
(PD-L1) quickly subverted the standard of treatment in Non-Small Cell Lung Cancer …

Age, sex, and specific gene mutations affect the effects of immune checkpoint inhibitors in colorectal cancer

A Lin, H Zhang, X Hu, X Chen, G Wu, P Luo… - Pharmacological …, 2020 - Elsevier
The effect of age and sex on the predictive value of colorectal cancer (CRC) patients treated
with immune checkpoint inhibitors (ICIs) has been controversial, and the effect of specific …